Stimuliver
Dagmara Szkolnicka is a co-founder and CSO at Stimuliver. Prior to that, Dagmara worked as a Postdoctoral Researcher in Virology at CHUV, a Fashion Model at The Model Team Ltd, and a Research Fellow at The University of Edinburgh. Dagmara also served as a Research Assistant at Edinburgh Napier University. Dagmara holds a PhD in Stem Cell Biology, an MSc in Drug Design and Biomedical Sciences, and a BSc (Hons) in Microbiology and Biotechnology.
This person is not in any teams
Stimuliver
Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list. Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans. The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.